Wegovy Versus Mounjaro What Is Different

Weight gain is not simply a matter of appearance but a health issue connected to type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease. When people who hit a wall despite sufficient diet and exercise come to the clinic, the question I hear most often lately is precisely the difference between Wegovy and Mounjaro. You’ve often heard the names, but how exactly the two drugs work differently in our bodies, and why one is more recommended for certain people, are surprisingly not well known. In this article, I’ll organize the mechanisms and differences of the two drugs at the level of general medical information.

Wegovy and Mounjaro are both prescription medicines that require a doctor’s prescription. They are not drugs to obtain or adjust the dose of at will through the internet or acquaintances, but treatments that can only be started after confirming indications, contraindications, and comorbidities. Both drugs are authorized for adults with obesity or overweight accompanied by comorbidities, as adjunctive therapy combined with diet and exercise. In other words, the starting point is that the drug does not replace lifestyle management but assists it.

Before starting the drug, we confirm a history of medullary thyroid cancer or multiple endocrine neoplasia, a past history of pancreatitis, whether you are planning a pregnancy, and so on. Such pre-checks are not a formality but an essential process for safety.

Wegovy’s ingredient is semaglutide, classified as a GLP-1 receptor agonist. GLP-1 is a hormone secreted by the intestines when we eat food; it acts on the brain’s appetite center to increase satiety and slows gastric emptying so that food goes down slowly. At the same time, it is involved in blood sugar control. Semaglutide acts on the same receptor in a way similar to this GLP-1, on the principle of helping you feel satisfied even while eating less.

In clinical studies, semaglutide was reported to produce meaningful weight loss when used together with diet·exercise, and an effect of lowering cardiovascular event risk was also reported. The U.S. FDA authorized a high-dose semaglutide formulation for chronic weight management in 2021 (FDA, 2021). Because it has been used for a relatively long time, the point that long-term data has accumulated is often mentioned.

Administration is usually by once-weekly subcutaneous injection, and it is not started at the maximum dose from the beginning but raised stepwise while watching gastrointestinal adaptation. This gradual dose increase is a standard method to reduce early discomforts such as nausea.

Mounjaro’s ingredient is tirzepatide, a dual agonist that acts simultaneously on the two hormone receptors GLP-1 and GIP. Here, GLP-1, as with Wegovy, handles appetite suppression and blood sugar control, and the additionally acting GIP is another gut hormone involved in insulin secretion and lipid·metabolic regulation. Touching both signals together is the biggest structural difference from a single agonist.

Tirzepatide was first authorized by the U.S. FDA in 2022 as a GIP·GLP-1 dual agonist for blood sugar control in type 2 diabetes (FDA, 2022), and afterward the same ingredient received separate authorization for a weight management indication as well. In a head-to-head comparative trial (SURMOUNT-5), tirzepatide was reported to show greater average weight loss than semaglutide (NEJM·Eli Lilly, 2025). However, this is an average value, and individual differences in response can be large.

The administration method is, as with Wegovy, a once-weekly subcutaneous injection, and likewise starts at a low dose and is gradually increased. It is often considered for those with accompanying diabetes or metabolic syndrome because this drug is involved in blood sugar and metabolic indicators overall.

The following table organizes the key differences between the two drugs. I recommend reading it with attention to the difference in the hormones acted on rather than to the figures.

Looking at the table alone, Mounjaro may always seem superior, but in care we do not decide so simply. We consider the side-effect pattern, underlying conditions, target weight, and cost and sustainability together to find the choice that fits one person. If you’re curious about weight management overall, looking together at the diet injection guide and an explanation of how the GLP-1 diet injection works helps.

I’ve grouped and organized the questions I hear repeatedly in the clinic. This is general information, and the answers can differ depending on individual circumstances.

• Which is more effective. Looking only at average weight loss, the tirzepatide figure was reported to be greater in the comparative trial. However, an average does not guarantee an individual’s result, and the more suitable drug can differ depending on side-effect tolerability and comorbidities.
• Can I take both drugs together. Both drugs are once-weekly GLP-1-class injectables, so they are not used simultaneously. You choose one and proceed in a tailored way.
• What are the side effects. For both drugs, gastrointestinal symptoms such as nausea, vomiting, constipation, and diarrhea are commonly reported. They generally tend to decrease over time, but rarely serious adverse reactions such as pancreatitis have been reported, so monitoring by a specialist is needed.

If you’re unsure whether to start a drug and, if you do, which drug suits you, you may also feel free to ask through Inquire about obesity treatment consultation.

I want to emphasize again the point that both drugs are authorized as adjunctive therapy combined with diet and exercise. The weight loss results of the clinical trials are also figures that came out in a state where lifestyle management was done together. Getting the injection does not mean you don’t have to mind your meals and activity; rather, in this period you need to pay even more attention to protein intake and maintaining muscle strength in order to reduce muscle loss.

I also speak frankly about the changes after discontinuation. There are reports that weight increased again after stopping a GLP-1-class drug, and it is important to set up a long-term management plan together from when you start the drug. If you have repeatedly become frustrated due to difficulty controlling appetite, you may also start with a consultation about difficulty in appetite control. In my clinical experience, the more someone views the drug and lifestyle as one bundle, the more the results tend to be maintained stably.

In particular, during periods of large hormonal change, weight management can become even trickier. If you’re curious about this part, I recommend reading along with an article on menopause and weight change.

Wegovy acts on a single hormone, and its relatively long-accumulated use experience and long-term data are mentioned as strengths, while Mounjaro acts on two hormones at once and was reported to show greater average weight loss in a comparative trial. Neither is the right answer for everyone, and ultimately the key is what fits my health condition better. At Apgujeong Wooahan Women’s Clinic, we look at underlying conditions and lifestyle patterns together and guide the choice that fits the individual. If you have questions before starting, please inquire through Apply for a specialist consultation.

Written by: Lee Dong-hee, Director · Obstetrics and Gynecology Specialist · View medical staff profile

First published August 21, 2025 · Last reviewed May 30, 2026

References: FDA Wegovy authorization data (2021), FDA Mounjaro authorization data (2022), SURMOUNT-5 comparative trial report NEJM·Eli Lilly (2025)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.